Frozen Leukopaks® are collected from IRB consented healthy donors at our FDA-registered Stem Cell Collection Center. Using the Spectra Optia® Apheresis System, cell-rich peripheral blood mononuclear cells (PBMCs) are extracted using a continuous flow centrifugation system directly into a sterile collection bag containing the anticoagulant ACD-A. Besides the PBMCs, which consist of lymphocytes and monocytes, each Leukopak® will also contain minimal amounts of granulocytes and red blood cells.
The percentage of cells can vary from donor to donor. The following are average cell populations for a single donor Leukopak® prior to cryopreservation:
• T cells - 55% (range 45-60%)
• Monocytes - 27% (range 10-30%)
• B cells - 9% (5-15%)
• NK cells - 8% (range 5-10%)
• CD34+ stem cells - 0.1% (range 0.1-0.5%)
• Granulocytes - 2.3% (range 0.6-10%)
• Hematocrit - 3% (range 2-3.5%)
Once collected, Leukopaks® are quickly frozen in a medium containing the cryoprotective agent CryoStorTM (10% DMSO) using a controlled rate freezer to ensure maximum viability.
Total nucleated cell (TNC) counts and viability testing are performed prior to cryopreservation. For optimal cell recovery and viability, we recommend following our Thawing Protocol found under the Technical Resources tab. Deviations from this protocol can compromise viability and cell recovery.
For global shipments, we highly recommend shipping Frozen Leukopaks® in an LN2 cryoshipper to maintain proper temperatures for the duration of the transit time. Upon arrival, Frozen Leukopaks® should be stored in the vapor phase of liquid nitrogen or thawed immediately for use.
Design the right Leukopak® for your research needs. View our custom orders to see what options we have available.
|Cell and Tissue Source||Peripheral Blood|
|Cell Type||Mononuclear Cells|
|Donor Attributes||HIV-, HepB-, HepC-|
|Viability||≥95% by Flow Cytometry Prior to Cryopreservation|
|Contains||CryoStor™ CS10 (10% DMSO)|
Product Information Sheet
Certificate of Analysis
Material Safety Data Sheet
Figure 1. Viability comparison, as determined by PI staining, of fresh and thawed Leukopaks®. Average viability of fresh Leukopaks® taken at the time of collection was 97.56% while the average post-thaw viability taken 7 days after cryopreservation was 96.33%.